Metabolic syndrome and the risk of preclinical heart failure: Insights after 17 years of follow-up from the STANISLAS Cohort

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Sharma, A (Author) Other; Razaghizad, A (Author) Other; Ferreira, JP (Author) FMUP; Machu, J (Author) Other; Bozec, E (Author) Other; Girerd, N (Author) Other; Rossignol, P (Author) Other; Zannad, F (Author) Other

Journal

Title: Cardiology

ISSN: 0008-6312

Publisher: Karger

Other information

Authenticus ID: P-00W-BYV

DOI: 10.1159/000523717

Abstract (EN): <jats:p>Background We used data from participants initially free of clinical cardiovascular disease in the STANISLAS cohort to evaluate the association between metabolic syndrome (MS) and development of preclinical heart failure (HF). Methods and Results The STANISLAS cohort is a single¿center familial longitudinal cohort composed of 1006 families from the Nancy region of France (median follow-up of 17 years [1993-2016]). Age and sex matched logistic regression models and inverse probability weighting models were used to determine the association of MS and preclinical HF. Among 944 adult patients at the final visit, those with baseline MS, compared to patients who developed MS and those without MS, were more likely to be older (63 vs 61 vs 59 years of age) and male (73% vs 55% vs 45%). The risk of preclinical HF was numerically increased, compared to patients without MS, among patients who developed MS (adjusted odds ratio [aOR] 1.56, 95% CI 1.00-2.43) and patients with MS at baseline (aOR 2.27, 95% CI 1.07-4.81). Among the individual components of MS, the risk of preclinical HF was elevated in individuals with baseline hypertension (aOR 3.19, 95% CI 1.80-5.63) and baseline elevated waist circumference (aOR 2.59, 95% CI 1.47-4.57). Conclusion Given the high risk of mortality when patients with metabolic syndrome or elevated fasting glucose become established with HF failure, HF prevention remains an important public health concern. Evaluation of early aggressive lifestyle and possibly medical intervention among patients free of cardiovascular disease with an obese-hypertensive phenotype to prevent future HF development is warranted. </jats:p>

Language: English

Type (Professor's evaluation): Scientific